by Marisa Wexler, MS | Feb 2, 2026 | Myeloma News
The U.S. Food and Drug Administration (FDA) has granted fast-track designation to QTX-2101, an oral formulation of an approved chemotherapy drug, as a potential treatment for acute promyelocytic leukemia (APL), a form of blood cancer. The FDA gives this designation to...
by MM360 Staff | Feb 1, 2026 | Uncategorized
Source: CURE articles Post Content Read More
by MM360 Staff | Jan 31, 2026 | Uncategorized
Source: CURE articles Post Content Read More
by MM360 Staff | Jan 31, 2026 | Uncategorized
Source: CURE articles Post Content Read More
by MM360 Staff | Jan 31, 2026 | Uncategorized
Source: CURE articles Post Content Read More